CAS: 57524-89-7; Cortisol 17-Valerate

该化合物是具有抗炎和免疫抑制特性的合成可热类固醇,主要用于皮肤配方,以治疗各种皮肤状况,包括乳胶,皮肤炎和皮质虫.该物质是水分松的衍生物,经添加甘蓝酯后修改,可增加其效力和皮肤渗透. 甘蓝酸酯是具有抗炎和免疫抑制作用的合成可热类固醇,主要用于皮肤配方,主要用于皮肤配方,以治疗各种皮肤状况,包括乳胶,皮质炎和皮质虫.该物质是水分松的衍生物,通过添加甘蓝酸酯来修改,从而增加其效力和皮肤渗透力和皮肤渗透力. 与所有园艺类固醇类相比,必须遵循施用准则,以尽量减少潜在风险,例如减少炎症,抑制免疫反应和促进血管抑制的能力.一般是作为时用奶油,膏或润滑剂配制成,以便进行局部吸收,同时进行局部处理;已知化合物的副作用相对较低.与长期使用可导致皮肤萎缩或其他当地有害影响.与所有花类固醇类动物一样,必须遵循施用准则,以尽量减少潜在风险.Hycorticolmononeonevalenoone vleated被归入化学鉴定数据库,用于575-89-7的化学用途.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号600-57-7 11β-羟孕酮

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:WO-2022226312-A1
    优先权日:2021-04-22
    标 题:Combination nucleotide pool depletion for treatment of viral infections and cancers
    发明人:KUMAR VIKRAM; HESSON DAVID; DEMAREST JAMES
    权利人:CLEAR CREEK BIO INC
    摘要:The invention provides methods of treating cancers and viral infections by providing a combination of agents that inhibit both nucleotide synthesis and nucleotide salvage in the cells of a subject to prevent cancer proliferation and viral replication. The invention provides methods of depleting nucleotide pools by using both inhibitors of dihydroorotate dehydrogenase (DHODH), such as brequinar, which block synthesis of pyrimidine-based nucleotides, in combination of one or more nucleotide salvage inhibitors, for example deoxycytidine kinase (dCK) inhibitors, Equilibrative nucleoside transporter (ENT) inhibitors, and Uridine-cytidine kinase (UCK) inhibitors, which inhibit salvage of purine and/or pyrimidine-based nucleotides or nucleosides

    专利号:US-9051302-B2
    优先权日:2008-01-15
    标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
    发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
    权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
    摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

    专利号:US-11850220-B2
    优先权日:2020-05-19
    标题 :Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
    发明人:PANDA SIVA
    权利人:UNIV RES INST INC AUGUSTA
    摘要:Disclosed herein as ibuprofen hybrid conjugates and methods of their use to reduce inflammation, pain, and fever. The ibuprofen conjugates have potent anti-inflammatory and analgesic properties with low potential for ulcerogenic activity. An exemplary compound is an ibuprofen-amino acid-4-aminophenol hybrid. Also disclosed are methods of treating or reducing inflammation, pain, and fever in a subject.

    专利号:US-2013261317-A1
    优先权日:2010-09-27
    标题 :Methods for preparing synthetic bile acids and compositions comprising the same
    发明人:MORIARTY ROBERT M; RAO PHOTON
    权利人:MORIARTY ROBERT M; RAO PHOTON; KYTHERA BIOPHARMACEUTICALS INC
    摘要:This invention relates generally to methods for preparing certain bile acids from non-mammalian sourced starting materials as well as to synthetic bile acids and compositions comprising such acids wherein the acids are characterized by a different C 14 population than naturally occurring bile acids as well as being free from any mammalian pathogens. This invention is also directed to the synthesis of intermediates useful in the synthesis of such bile acids. Accordingly, the C ring of the steroidal scaffold is oxidized to provide a synthetic route and intermediates to DCA. This invention also provides synthetic methods for preparing deoxycholic acid or a salt thereof starting from aromatic steroids such as estrogen, equilenin, and derivatives thereof. This invention is also directed to intermediates such as 12-oxo or delta-9,11-ene steroids as well as novel processes for their preparation. In preferred embodiments, bile acids are provided herein which have substituents on the B-ring and/or D-ring side chain and optionally on the hydroxy group of the A-ring.

    专利号:WO-9709067-A1
    优先权日:1995-09-05
    标 题 :Combination of 5-lipoxygenase and leukotriene synthesis inhibitors with glucocorticosteroids
    发明人:BURCHARDT ELMAR-REINHOLD; MUELLER-PEDDINGHAUS REINER
    权利人:BAYER AG; BURCHARDT ELMAR REINHOLD; MUELLER PEDDINGHAUS REINER
    摘要:The combination is disclosed of 5-lipoxygenase inhibitors as direct action lipoxygenase inhibitors (LOI) or of leukotriene synthesis inhibitors (LSI) with glucocorticosteroids (GCS). This combination is suitable for treating and preventing various acute and chronic inflammatory processes, in particular of the respiratory tract, and may therefore be used as a medicament, in particular for treating asthma.

    专利号:US-5922335-A
    优先权日:1995-05-15
    标 题:Uses for ascorbyl-phosphoryl-cholesterol in topical compositions
    发明人:PTCHELINTSEV DMITRI
    权利人:AVON PROD INC
    摘要:Novel uses of 3'-(L-ascorbyl-2-o-phosphoryl)-cholesterol, 3'-(L-ascorbyl-3-o-phosphoryl)-cholesterol, structural or functional isomers thereof and salts thereof (referred to collectively as 'APC compounds') are disclosed. Such novel uses include a method of reducing epidermal synthesis of abnormal elastin, especially epidermal synthesis of abnormal elastin that results from exposure to UV radiation. Also disclosed is a novel method of stimulating keratinocyte formation of triglycerides. In addition, a novel method of achieving antioxidant activity, both in the skin and also in topical compositions, is disclosed.
    江苏联环药业集团公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.lhpharma.com
    电话: 0514-87814842 87829556👤
    📞江苏联环药业集团公司 ⚠️参考联系方式

    销售电话:0514-87814842 87829556
    邮箱:xsb@lhpharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    杭州鼎燕化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.dingyanchem.com
    企业联系电话:18267553885👤
    📞杭州鼎燕化工有限公司 ⚠️参考联系方式
    联系人:林女士
    电话:18267553885
    手机:18267553885
    传真:0571-87156470
    邮箱:sales@dingyanchem.com
    通信地址: 杭州市江干区下沙19号大街571号下沙电子商务园4A601-602室
    邮编: 310018
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:杭州市江干区下沙19号大街571号下沙电子商务园4A601-602室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Sefton J, Loder JS, Kyriakopoulos AA. Clinical evaluation of hydrocortisone valerate 0.2% ointment. Clin Ther. 1984;6(3):282-93. 21(5):695-8. 1(4912):530-1.
    4: Sefton J, Kyriakopoulos AA. Comparative efficacy of hydrocortisone valerate 0.2 percent ointment in the treatment of atopic dermatitis. Cutis. 1983 Jul;32(1):89-91, 94. 38(8):604-6. doi: 10.1046/j.1365-4362.1999.00759.x. 12(1):58. doi: 10.1111/j.1600-0536.1985.tb01048.x. 27(2):190-5. doi: 10.1378/chest.27.2.190. 55(1):145-63. doi: 10.2165/00003495-199855010-00009. 38(6):404-7. 57(21):3463-5.

    合成参考文献


    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    参考文献:10.1136/gut.1.3.217
    摘要:LENNARD-JONES JE, LONGMORE AJ, NEWELL AC, WILSON CW, JONES FA. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960 Sep;1():217–22.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知